Structure-activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (glycine site) receptor antagonists.: 1.: Heterocyclic substituted 5-alkyl derivatives

被引:74
作者
Fray, MJ [1 ]
Bull, DJ [1 ]
Carr, CL [1 ]
Gautier, ECL [1 ]
Mowbray, CE [1 ]
Stobie, A [1 ]
机构
[1] Pfizer Ltd, Global Res & Dev, Dept Discovery Chem, Sandwich CT13 9NJ, Kent, England
关键词
D O I
10.1021/jm001124p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 6,7-dichloro-1,4-dihydro-(1H, 4H)-quinoxaline-2,3-diones (1-17) were prepared in which the 5-position substituent was a heterocyclylmethyl or 1-(heterocyclyl)-1-propyl group. Structure-activity relationships were evaluated where binding affinity for the glycine site of the N-methyl-D-aspartate (NMDA) receptor was measured using the specific radioligand [H-3]- L-689,560, and functional antagonism was demonstrated by inhibition of NMDA-induced depolarizations of rat cortical wedges. The ability to prevent NMDA-induced hyperlocomotion in mice in vivo was measured for selected compounds. Binding affinity increased significantly if the heterocyclic group, e.g. 1,2,3-triazol-1-yl could participate in accepting a hydrogen bond from the receptor. It was difficult to obtain compounds with adequate aqueous solubility and strategies to improve it were investigated. The most potent compound in this series, 6,7-dichloro-5-[1-( 1,2,4-triazol-4-yl)propyl]-1,4-dihydro-(1H, 4H)-quinoxaline-2,3-dione (17) (binding IC50 = 2.6 nM; cortical wedge EC50 = 90 nM), inhibited NMDA-induced hyperlocomotion in mice (6/9 protected at 20 mg/kg iv). Pharmacokinetic parameters, including extent of brain penetration, for 11 and 17 are reported.
引用
收藏
页码:1951 / 1962
页数:12
相关论文
共 39 条
[1]  
ABENHAIM D, 1994, HETEROCYCLES, V38, P793
[2]   HYDROGEN-BONDING .9. SOLUTE PROTON DONOR AND PROTON ACCEPTOR SCALES FOR USE IN DRUG DESIGN [J].
ABRAHAM, MH ;
DUCE, PP ;
PRIOR, DV ;
BARRATT, DG ;
MORRIS, JJ ;
TAYLOR, PJ .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1989, (10) :1355-1375
[3]   Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke [J].
Albers, GW ;
Clark, WM ;
Atkinson, RP ;
Madden, K ;
Data, JL ;
Whitehouse, MJ .
STROKE, 1999, 30 (03) :508-513
[4]   5-Aminomethylquinoxaline-2,3-diones. Part II: N-aryl derivatives as novel NMDA/glycine and AMPA antagonists. [J].
Auberson, YP ;
Acklin, P ;
Allgeier, H ;
Biollaz, M ;
Bischoff, S ;
Ofner, S ;
Veenstra, SJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (01) :71-74
[5]   GENERAL-APPROACH TO HIGHLY FUNCTIONALIZED BENZYLIC ORGANOMETALLICS OF ZINC AND COPPER [J].
BERK, SC ;
KNOCHEL, P ;
YEH, MCP .
JOURNAL OF ORGANIC CHEMISTRY, 1988, 53 (24) :5789-5791
[6]  
Bru-Magniez N., Patent: E P, Patent No. [0385850 A2, 0385850]
[7]  
Bull DJ, 1996, SYNLETT, P647
[8]   Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: Potent and systemically active antagonists for the glycine site of the NMDA receptor [J].
Cai, SX ;
Kher, SM ;
Zhou, ZL ;
Ilyin, V ;
Espitia, SA ;
Tran, M ;
Hawkinson, JE ;
Woodward, RM ;
Weber, E ;
Keana, JFW .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (05) :730-738
[9]   RADICAL SPIROCYCLIZATION - SYNTHESIS OF AN APPROPRIATELY OXYGENATED SPIRO COMPOUND RELATED TO THE ANTITUMOR ANTIBIOTIC FREDERICAMYCIN-A [J].
CLIVE, DLJ ;
ANGOH, AG ;
BENNETT, SM .
JOURNAL OF ORGANIC CHEMISTRY, 1987, 52 (07) :1339-1342
[10]  
Dannhardt G, 1998, CURR MED CHEM, V5, P253